ArticleMolecular neurobiology2025
Tetramethylpyrazine Promotes Functional Recovery after Spinal Cord Injury by Regulating 5-Methylcytosine RNA Modification via the NSUN2-XBP1 Axis.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review
- Transcriptomics Insights into Spinal Cord Injury for Therapy Development.International journal of molecular sciences · 2026Review
- Targeting Dnmt3a/m5C/RelA Axis Attenuates Microglia Inflammatory Response and Improves Postoperative Recovery in Chronic Compressive Cervical Spinal Cord Injury.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Integrative analysis identifies Hspa5 as a key regulator of the ERS/UPR-immune axis in spinal cord injury.Frontiers in genetics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundSpinal cord injury (SCI) is a devastating condition with limited therapeutic options. Tetramethylpyrazine (TMP) has shown therapeutic potential in mitigating SCI-related damage. This study investigates the role of TMP in regulating 5-methylcytosine (m
methodsA rat model of SCI was induced via contusion injury, and TMP was administered intraperitoneally for 28 days. Functional recovery was evaluated using the Basso-Beattie-Bresnahan (BBB) locomotor rating scale. Histopathological changes were assessed by hematoxylin-eosin (HE) staining, while inflammatory cytokines (IL-1β, IL-6, TNF-α) and oxidative stress markers (SOD, MDA) were quantified using enzyme-linked immunosorbent assay (ELISA) and colorimetric assays. In vitro, PC12 cells were exposed to lipopolysaccharide (LPS) to model SCI, and TMP's effects on apoptosis and inflammation were analyzed via flow cytometry and ELISA. Molecular docking, m
resultsTMP treatment significantly improved motor function, reduced inflammation, and alleviated oxidative stress in SCI rats. In vitro, TMP dose-dependently reduced apoptosis and inflammatory cytokine levels in LPS-induced PC12 cells. TMP downregulated NSUN2 expression, leading to reduced m
conclusionsTMP promotes functional recovery after SCI by modulating m
Indexed as
Identifiers
41254347What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.